12/2/2020

Metastatic

HER 2+

1st Line

2nd Line

HER 2-

1st Line

2nd Line

Adjuvant

Localized

No Trials Currently Available

IRB# 20600
A Randomized, Double-blind, Placebo-controlled Phase 3 trial of Pembrolizumab versus Placebo in participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy.

IRB# 20901
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signal Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 18340
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signal Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

Key

Open for Enrollment
In Development
Enrollment on Hold

GI Esophageal / Gastric

http://www.ohsu.edu/research/rda/so/knight.php